Hyponatremia is a common electrolyte disorder associated with potentially serious or life-threatening consequences. Serum osmolality and sodium concentration [Na+] are regulated by thirst, the hormone arginine vasopressin (AVP), and renal water and sodium handling. Hyponatremia is frequently caused by dysregulation of AVP, which accompanies disorders of water retention, such as congestive heart failure (CHF) and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Clinical trials with AVP receptor antagonists have confirmed the important role of AVP in the pathophysiology of hyponatremia and suggest these agents are efficacious in treating hyponatremia associated with SIADH, cirrhosis, and CHF. Acting directly at AVP receptors in the renal tubules, these agents promote aquaresis – the electrolyte-sparing excretion of free water – in patients with hyponatremia. In clinical trials, AVP receptor antagonists have been shown to increase the serum [Na+] and urine output while decreasing urine osmolality.

Keywords:
Hyponatremia, Vasopressin, Salt-water balance, Sodium, Syndrome of inappropriate secretion of antidiuretic hormone, Antidiuretic hormone, Homeostasis
1.
Kennedy PG, Mitchell DM, Hoffbrand BI: Severe hyponatraemia in hospital inpatients. Br Med J 1978;2:1251–1253.
2.
Anderson RJ, Chung HM, Kluge R, Schrier RW: Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164–168.
3.
Gill G, Leese G: Hyponatraemia: biochemical and clinical perspectives. Postgrad Med J 1998;74:516–523.
4.
Tierney WM, Martin DK, Greenlee MC, Zerbe RL, McDonald CJ: The prognosis of hyponatremia at hospital admission. J Gen Intern Med 1986;1:380–385.
5.
Hawkins RC: Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003;337:169–172.
6.
Baran D, Hutchinson TA: The outcome of hyponatremia in a general hospital population. Clin Nephrol 1984;22:72–76.
7.
Terzian C, Frye EB, Piotrowski ZH: Admission hyponatremia in the elderly: factors influencing prognosis. J Gen Intern Med 1994;9:89–91.
8.
Fraser CL, Arieff AI: Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997;102:67–77.
9.
Verbalis JG: Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003;17:471–503.
10.
Arnauld E, Vincent JD, Dreifuss JJ: Firing patterns of hypothalamic supraoptic neurons during water deprivation in monkeys. Science 1974;185:535–537.
11.
Ferguson JW, Therapondos G, Newby DE, Hayes PC: Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) 2003;105:1–8.
12.
Andreoli TE: Water: normal balance, hyponatremia, and hypernatremia. Ren Fail 2000;22:711–735.
13.
Fried LF, Palevsky PM: Hyponatremia and hypernatremia. Med Clin North Am 1997;81:585–609.
14.
Robinson AG: Disorders of antidiuretic hormone secretion. Clin Endocrinol Metab 1985;14:55–88.
15.
Luckey AE, Parsa CJ: Fluid and electrolytes in the aged. Arch Surg 2003;138:1055–1060.
16.
Davison JM, Shiells EA, Philips PR, Lindheimer MD: Serial evaluation of vasopressin release and thirst in human pregnancy. Role of human chorionic gonadotrophin in the osmoregulatory changes of gestation. J Clin Invest 1988;81:798–806.
17.
Freda BJ, Davidson MB, Hall PM: Evaluation of hyponatremia: a little physiology goes a long way. Cleve Clin J Med 2004;71:639–650.
18.
Yeates KE, Singer M, Morton AR: Salt and water: a simple approach to hyponatremia. CMAJ 2004;170:365–369.
19.
Adrogué HJ, Madias NE: Hyponatremia. N Engl J Med 2000;342:1581–1589.
20.
Palmer BF: Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 2003;14:182–187.
21.
Bartter FC, Schwartz WB: The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967;42:790–806.
22.
Betjes MG: Hyponatremia in acute brain disease: the cerebral salt wasting syndrome. Eur J Intern Med 2002;13:9–14.
23.
Soupart A, Decaux G: Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol 1996;46:149–169.
24.
Ginés P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, Liard JF, Martin PY, Schrier RW: Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998;28:851–864.
25.
Miller PD, Linas SL, Schrier RW: Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980;243:2513–2515.
26.
Janicic N, Verbalis JG: Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 2003;32:459–481.
27.
Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM: Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000;106:107–116.
28.
Lee CR, Watkins ML, Patterson JH, Gattis W, O’Connor CM, Gheorghiade M, Adams KF Jr: Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003;146:9–18.
29.
Ishikawa SE, Schrier RW: Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) 2003;58:1–17.
30.
Ecelbarger CA, Chou CL, Lee AJ, DiGiovanni SR, Verbalis JG, Knepper MA: Escape from vasopressin-induced antidiuresis: role of vasopressin resistance of the collecting duct. Am J Physiol 1998;274:F1161–F1166.
31.
Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW: Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263–266.
32.
Camps J, Sola J, Arroyo V, Perez-Ayuso RM, Gaya J, Rivera F, Rodes J: Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. Gastroenterology 1987;93:498–505.
33.
Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D: Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999;10:647–663.
34.
Thibonnier M, Coles P, Thibonnier A, Shoham M: The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001;41:175–202.
35.
Manning M, Sawyer WH: Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 1989;114:617–632.
36.
Palm C, Reimann D, Gross P: The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc Res 2001;51:403–408.
37.
Palm C, Gross P: V2-vasopressin receptor antagonists – mechanism of effect and clinical implications in hyponatraemia. Nephrol Dial Transplant 1999;14:2559–2562.
38.
Ohnishi A, Orita Y, Okahara R, Fujihara H, Inoue T, Yamamura Y, Yabuuchi Y, Tanaka T: Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993;92:2653–2659.
39.
Naitoh M, Risvanis J, Balding LC, Johnston CI, Burrell LM: Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. Cardiovasc Res 2002;54:51–57.
40.
Burrell LM, Phillips PA, Risvanis J, Chan RK, Aldred KL, Johnston CI: Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol 1998;275:H176–H182.
41.
Naitoh M, Suzuki H, Murakami M, Matsumoto A, Arakawa K, Ichihara A, Nakamoto H, Oka K, Yamamura Y, Saruta T: Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994;267:H2245–H2254.
42.
Nishikimi T, Kawano Y, Saito Y, Matsuoka H: Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 1996;27:275–282.
43.
Fujisawa G, Ishikawa S, Tsuboi Y, Okada K, Saito T: Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int 1993;44:19–23.
44.
Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T: Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994;46:237–244.
45.
Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J; VPA Study Group: Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933–939.
46.
Wong F, Blei AT, Blendis LM, Thuluvath PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37:182–191.
47.
Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690–2696.
48.
Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963–1971.
49.
Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, Saruta T, Yoshida S: Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997;82:1054–1057.
50.
Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, Koizumi F, Chau T, Okada K, Yamamura Y, Tanaka T: Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998;63:561–570.
51.
Risvanis J, Naitoh M, Johnston CI, Burrell LM: In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat. Eur J Pharmacol 1999;381:23–30.
52.
Tomura Y, Tahara A, Tsukada J, Yatsu T, Uchida W, Iizumi Y, Honda K: Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin Exp Pharmacol Physiol 1999;26:399–403.
53.
Verbalis JG, Bisaha JG, Smith N: Novel vasopressin V1A and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. J Am Soc Nephrol 2004;15:356A.
54.
Verbalis JG, Ghali JK, Gross P, Long WA, Smith N: Conivaptan, a novel arginine vasopressin antagonist, produced aquaresis and increased serum sodium concentration in patients with euvolemic and hypervolemic hyponatremia. Pharmacotherapy 2005;25:1454.
55.
Ghali JK, Bisaha JG, Smith N: Efficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia. J Am Soc Nephrol 2004;15:355A.
56.
Gross P, Bisaha JG, Smith N: Conivaptan, a novel V1A and V2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia. J Am Soc Nephrol 2004;15:355A.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.